Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth

Executive Summary

Wyeth's latest direct-to-consumer advertising campaign for its estrogen franchise suggests emerging use of unbranded ads for leading products in mature markets

You may also be interested in...



Hormone Therapy Heart Disease Risk Negligible For Women Near Menopause

A secondary analysis of the Women's Health Initiative randomized controlled trials of hormone therapy could have favorable implications for Wyeth's menopause franchise

Hormone Therapy Heart Disease Risk Negligible For Women Near Menopause

A secondary analysis of the Women's Health Initiative randomized controlled trials of hormone therapy could have favorable implications for Wyeth's menopause franchise

Wyeth Urges Halt to Hormone Compounding, Questioning Its Safety

Wyeth's citizen petition to the FDA urging it to stop compounding pharmacists from producing "bioidentical hormone replacement therapy" focuses on safety concerns about the practice

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel